Registration of securities issued in business combination transactions

9. Stockholders' Equity (Details Narrative)

v3.19.1
9. Stockholders' Equity (Details Narrative) - USD ($)
 2 Months Ended 3 Months Ended 12 Months Ended
Mar. 15, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Proceeds from warrant exercises       $ 1,480,000 $ 0
Warrant-based expense for services   $ (26,576) $ 4,917 $ 10,206 $ (126,316)
Series B Preferred Stock [Member]          
Stock converted, shares converted       300,000 200,000
Stock converted, shares issued       300,000 200,000
Warrants [Member]          
Warrants exercised       400,000 0
Warrants exercised, stock issued       400,000 0
Pharmsynthez [Member]          
Debt converted, stock issued 100,000        
Debt converted, amount converted $ 500,000        
Serum Institute Warrants [Member]          
Warrants outstanding       539,202 646,249
Warrant-based expense for services       $ 10,000 $ (100,000)
Warrant weighted average exercise price       $ 10.41  
Warrant expiration date range       December 2019 through May 2021  
Financing Agreements [Member]          
Warrants exercised       370,000 0
Warrants exercised, stock issued       370,000  
Proceeds from warrant exercises       $ 1,500,000  
Warrants outstanding       3,152,225 3,522,225
Warrant weighted average exercise price       $ 4.33 $ 4.30
Warrant expiration date range       July 1, 2020 through November 2021  
Warrants granted       0 0